Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FcγR- and CD9-dependent synapse-engulfing microglia in the thalamus drive cognitive impairment following cortical brain damage in mice.

Nature communications·2026
Same author

FcγR- and CD9-dependent synapse engulfing microglia in the thalamus drives cognitive impairment following cortical brain injury.

bioRxiv : the preprint server for biology·2026
Same author

Microglia-T cell interactions drive α-synuclein pathology in a Parkinson's disease mouse model.

Journal of neuroinflammation·2026
Same author

Healthcare Resource Utilization and Medical Costs in Pulmonary Arterial Hypertension Management in Japan: A Retrospective Study Using a Claims Database.

Pulmonary therapy·2026
Same author

Recovery of Motor Function via Intraspinal Detour Circuits following Unilateral Spinal Cord Injury.

European neurology·2025
Same author

Author Correction: Cellular senescence in white matter microglia is induced during ageing in mice and exacerbates the neuroinflammatory phenotype.

Communications biology·2025

Related Experiment Video

Updated: May 26, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Repulsive guidance molecule-a and demyelination: implications for multiple sclerosis.

Takekazu Kubo1, Shigeru Tokita, Toshihide Yamashita

  • 1Molecular Function and Pharmacology Laboratories, Pharmaceutical Business, Taisho Pharmaceutical Co., Ltd, 403, Yoshino-cho 1-Chome, Kita-ku, Saitama-shi, Saitama, 331-9530, Japan. takekazukubo@yahoo.co.jp

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology
|December 21, 2011
PubMed
Summary

Repulsive guidance molecule-a (RGMa) hinders central nervous system axon regeneration and promotes T cell activation in multiple sclerosis models. Targeting RGMa offers a novel therapeutic strategy for neurodegenerative and neuroinflammatory diseases.

More Related Videos

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Related Experiment Videos

Last Updated: May 26, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice
08:03

Myelin Oligodendrocyte Glycoprotein (MOG35-55) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice

Published on: April 15, 2014

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Drug development for neurodegenerative and neuroinflammatory diseases like multiple sclerosis (MS) and traumatic brain injury (TBI) is complex.
  • These diseases involve multiple pathological phases, necessitating therapeutic strategies targeting divergent pathophysiological processes simultaneously.
  • Repulsive guidance molecule-a (RGMa) has emerged as a molecule with distinct actions in the central nervous system (CNS) and immune system.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting RGMa for neurodegenerative and neuroinflammatory diseases.
  • To explore RGMa's dual role in inhibiting CNS axon regeneration and promoting autoimmune responses in MS.
  • To introduce RGMa as a novel intervention for conditions including MS and spinal cord injury (SCI).

Main Methods:

  • Investigated RGMa's role in CNS axon regeneration following SCI.
  • Examined RGMa's effect on CD4(+) T cell activation and CNS demyelination in a mouse model of MS (experimental autoimmune encephalomyelitis, EAE).

Main Results:

  • RGMa was found to inhibit the regeneration of injured CNS axons after SCI.
  • RGMa was shown to enhance CD4(+) T cell activation, contributing to CNS demyelination in the EAE model.
  • These findings highlight RGMa's distinct pathological actions in both neural injury and autoimmune processes.

Conclusions:

  • RGMa possesses multiple functions within the CNS and immune system.
  • Targeting RGMa presents a therapeutic opportunity to simultaneously address autoimmune reactions and axon injury.
  • RGMa blockade is proposed as a novel intervention for MS and SCI.